Olatoyosi Odenike, MD
Enriched profileProfessor of Medicine; Director, Leukemia Program · University of Chicago
Olatoyosi Odenike is Professor of Medicine; Director, Leukemia Program at University of Chicago. OpenAlex indexes 354 publications with 10,412 citations (h-index 46); ClinicalTrials.gov lists 19 registered studies with this person as an investigator.
Data verified 25 Aug 2026
Overview
Updated 27 Aug 2026
Olatoyosi Odenike is Professor of Medicine at University of Chicago, Department of Medicine. The public record shows 354 publications with 10,412 citations (h-index 46), centered on Leukemia (AML/ALL/CML/CLL), MDS / MPN. It also documents an investigator role on 19 registered clinical trials, industry payments reported by 10 companies.
- Most recent indexed publication: 2026 · Molecular cancer therapeutics
- Top research focus: Leukemia (AML/ALL/CML/CLL)
- 19 registered trials on ClinicalTrials.gov
- Open Payments reporting from 10 companies
Generated from the cited public record · current as of 27 Aug 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 5 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 27 Aug 2026
Listed as an investigator on 19 registered studies on ClinicalTrials.gov. The most recent:
- Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
Sponsor: National Cancer Institute (NCI)
- Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
Sponsor: National Cancer Institute (NCI)
Industry payments
Updated 27 Aug 2026
10 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Geron CorporationProgram year20252 payments
- SERVIER PHARMACEUTICALS LLCProgram year20244 payments
- SERVIER PHARMACEUTICALS LLCProgram year20237 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
100%Kinase inhibitor48.8%Jakafi84%Imatinib Mesylate17%Part D<11 patientsBCL-2 Inhibitor19.8%Venclexta100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 27 Aug 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Acute Lymphoblastic Leukemia with Myeloid Mutations Is a High-Risk Disease Associated with Clonal Hematopoiesis.
Blood cancer discovery
Article2024 - Dual Targeting of Apoptotic and Signaling Pathways in T-Lineage Acute Lymphoblastic Leukemia.
Clinical cancer research
Article2023
Online presence
Updated 27 Aug 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/olatoyosi-odenike-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - ResearchGate
researchgate.net/scientific-contributions/38474853_Olatoyosi_Odenike
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →researchgate.net ↗ - LinkedIn
linkedin.com/in/olatoyosi-odenike-0bb57883
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →linkedin.com ↗
Mentions by others
where others cite or feature them- Other
society.asco.org/people/olatoyosi-odenike-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →society.asco.org ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗ - YouTube
youtube.com/watch
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →youtube.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 27 Aug 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- MD
University of Ibadan College of Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uchicagomedicine.org ↗ - Board Certified
Medical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uchicagomedicine.org ↗ - Residency
Internal Medicine, University of Illinois at Chicago
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uchicagomedicine.org ↗ - Fellowship
Hematology/Oncology, University of Chicago Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uchicagomedicine.org ↗
Editorial & leadership roles
journal and society appointments- Director
Leukemia Program, University of Chicago Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uchicagomedicine.org ↗ - Member
American Society of Clinical Oncology (ASCO)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uchicagomedicine.org ↗ - Member
American Society of Hematology (ASH)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →uchicagomedicine.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗
Secondary affiliations
appointments beyond the home institution- Member
Medical Advisory Board, Aplastic Anemia and MDS International Foundation (AAMDSIF)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →aamds.org ↗
Media & interviews
press, podcasts and appearances- provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →onclive.com ↗
- "Pulling Back the Curtain: Olatoyosi Odenike, MD"
profile feature with audio Sound Bites, ASH Clinical News
2018verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ashclinicalnews.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Everett Vokes, MD
University of Chicago
Ralph Weichselbaum, MD
University of Chicago
Mary Rinella, MD
University of Chicago
Hedy Kindler, MD
University of Chicago